Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models

Friday, April 25, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of novel oral degraders targeting KAT6A, which have shown promising anti-cancer effects in pre-clinical studies. This first-in-class approach could pave the way for new cancer therapies. The findings highlight the potential of these degraders in addressing unmet medical needs in oncology.
Price reaction · baseline $0.8754 (2025-04-25T16:01:00.000Z) · hit during market hours · 1 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discovery of first-in-class oral degraders of KAT6A
  • Demonstrated anti-cancer activity in pre-clinical models
  • Potential for significant impact in cancer treatment

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Monisha Sivakumar, Sarah Pawley, Anthony Reichelderfer, Corey Basch, Jimin Park, Jessica Burtell, Chaoyi Xu, Min Wang, Chun Chen, Justin Kurian, Quincy Lewis, Vijay Devannah, Sina Rezazadeh, Joy Cote, Miles Cowart, Stephanie Rodgers, Amy Crossan, Joseph Rager, Koichi Ito, Sandy Geeganage, SangHyun Lee, Andrew Combs, Peggy Scherle, Andrew Buesking, Jack Carter

Frequently Asked Questions

What are KAT6A oral degraders?

KAT6A oral degraders are novel compounds designed to selectively degrade the KAT6A protein.

What was the outcome of the pre-clinical studies?

The pre-clinical studies demonstrated that these degraders exhibit anti-cancer activity.

Why is this discovery significant?

This discovery represents a first-in-class approach that could lead to new cancer therapies.

Who were the researchers involved in this study?

The study involved researchers Monisha Sivakumar, Sarah Pawley, and others.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare KAT6A cancer treatment oral degraders pre-clinical models
Last updated: Apr 25, 2025

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →